113 results
8-K
EX-99.1
LUMO
Lumos Pharma Inc
4 Jan 24
Regulation FD Disclosure
4:34pm
with Rick and our talented team to advance the company toward our clinical and strategic goals.”
Dr. Pitukcheewanont is a seasoned pediatric endocrinologist
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 Nov 23
Other Events
4:38pm
of PEM classification Annualized Height Velocity (AHV) Goals: Determine optimal dose for Phase 3 Primary Outcome Data (n = 82) – at 6 months on therapy … : Assess LUM-201 effect on endogenous GH pulsatility and Annualized Height Velocity (AHV) Evaluate PK/PD in children Goals: Confirm prior PK/PD data
8-K
EX-99.2
LUMO
Lumos Pharma Inc
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
of PEM strategy Evaluate reproducibility of PEM classification Annualized Height Velocity (AHV) Goals: Determine optimal dose for Phase 3 Primary … in children Goals: Confirm prior PK/PD data in adults & subset of Merck 020 trial Support future regulatory filings & commercialization OraGrowtH212
8-K
EX-99.2
8hkqn9g e2ki8
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.2
8v2gaud9fji
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.2
cqat6axq9ww
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
8-K
EX-99.2
blw6ky62tv830bka3
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
8-K
EX-99.2
p8kp6o
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
EX-99.2
0dig 21iyu4jtd
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
8-K
EX-99.2
eqr47d
10 May 22
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
4:47pm
8-K
EX-99.2
44ya e5y5
10 Mar 22
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
4:20pm
8-K
EX-99.2
2a51rugex gbemwdeh97
3 Nov 21
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
4:11pm